560 related articles for article (PubMed ID: 34448955)
1. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis.
Karb DB; Cummings LC
Curr Gastroenterol Rep; 2021 Aug; 23(10):17. PubMed ID: 34448955
[TBL] [Abstract][Full Text] [Related]
2. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators.
Konrad J; Eber E; Stadlbauer V
Paediatr Respir Rev; 2022 Jun; 42():9-16. PubMed ID: 33485777
[TBL] [Abstract][Full Text] [Related]
3. CFTR dysregulation drives active selection of the gut microbiome.
Meeker SM; Mears KS; Sangwan N; Brittnacher MJ; Weiss EJ; Treuting PM; Tolley N; Pope CE; Hager KR; Vo AT; Paik J; Frevert CW; Hayden HS; Hoffman LR; Miller SI; Hajjar AM
PLoS Pathog; 2020 Jan; 16(1):e1008251. PubMed ID: 31961914
[TBL] [Abstract][Full Text] [Related]
4. Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy.
McDonald CM; Reid EK; Pohl JF; Yuzyuk TK; Padula LM; Vavrina K; Altman K
Nutr Clin Pract; 2024 Apr; 39 Suppl 1():S57-S77. PubMed ID: 38429959
[TBL] [Abstract][Full Text] [Related]
5. Cystic Fibrosis, CFTR, and Colorectal Cancer.
Scott P; Anderson K; Singhania M; Cormier R
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326161
[TBL] [Abstract][Full Text] [Related]
6. Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome.
Marsh R; Dos Santos C; Hanson L; Ng C; Major G; Smyth AR; Rivett D; van der Gast C
Microbiol Spectr; 2023 Aug; 11(5):e0117523. PubMed ID: 37607068
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.
Bazett M; Honeyman L; Stefanov AN; Pope CE; Hoffman LR; Haston CK
Mamm Genome; 2015 Jun; 26(5-6):222-34. PubMed ID: 25721416
[TBL] [Abstract][Full Text] [Related]
8. The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.
Garg M; Ooi CY
Curr Gastroenterol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155088
[TBL] [Abstract][Full Text] [Related]
9. Celiac Disease in Patients With Cystic Fibrosis on Ivacaftor: A Case Series.
Hjelm M; Shaikhkhalil AK
J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):257-260. PubMed ID: 32304549
[TBL] [Abstract][Full Text] [Related]
10. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
[TBL] [Abstract][Full Text] [Related]
11. Fecal dysbiosis and inflammation in intestinal-specific Cftr knockout mice on regimens preventing intestinal obstruction.
Young SM; Woode RA; Williams EC; Ericsson AC; Clarke LL
Physiol Genomics; 2024 Mar; 56(3):247-264. PubMed ID: 38073491
[TBL] [Abstract][Full Text] [Related]
12. The gut microbiota in adults with cystic fibrosis compared to colorectal cancer.
Caley LR; Wood HM; Bottomley D; Fuentes Balaguer A; Wilkinson L; Dyson J; Young C; White H; Benton S; Brearley M; Quirke P; Peckham DG
J Cyst Fibros; 2024 Mar; 23(2):262-268. PubMed ID: 38104000
[TBL] [Abstract][Full Text] [Related]
13. Neonatal Gastrointestinal and Respiratory Microbiome in Cystic Fibrosis: Potential Interactions and Implications for Systemic Health.
Madan JC
Clin Ther; 2016 Apr; 38(4):740-6. PubMed ID: 26973296
[TBL] [Abstract][Full Text] [Related]
14. The Microbiome in Cystic Fibrosis Pulmonary Disease.
Françoise A; Héry-Arnaud G
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32403302
[TBL] [Abstract][Full Text] [Related]
15. The cystic fibrosis intestine.
De Lisle RC; Borowitz D
Cold Spring Harb Perspect Med; 2013 Sep; 3(9):a009753. PubMed ID: 23788646
[TBL] [Abstract][Full Text] [Related]
16. What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics?
van Dorst JM; Tam RY; Ooi CY
Nutrients; 2022 Jan; 14(3):. PubMed ID: 35276841
[TBL] [Abstract][Full Text] [Related]
17. Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota.
Lynch SV; Goldfarb KC; Wild YK; Kong W; De Lisle RC; Brodie EL
Gut Microbes; 2013; 4(1):41-7. PubMed ID: 23060053
[TBL] [Abstract][Full Text] [Related]
18. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
19. Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions.
Tam RY; van Dorst JM; McKay I; Coffey M; Ooi CY
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160099
[TBL] [Abstract][Full Text] [Related]
20. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
